

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/801,122	03/15/2004	Edward A. Neuwelt	720109.405	9179
500	7590 10/19/2006		EXAMINER	
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 5400			ZHANG, NANCY L	
			ART UNIT	PAPER NUMBER
SEATTLE, W	/A 98104		1614	

DATE MAILED: 10/19/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/801,122	NEUWELT, EDWARD A.				
Office Action Summary	Examiner	Art Unit				
	Nancy L. Zhang	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 15 Ma	arch 2004.					
·= · ·	_					
·—	<del>/ -</del>					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-24</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.	7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-24</u> are subject to restriction and/or e	lection requirement.					
Application Papers						
9)☐ The specification is objected to by the Examiner						
10)☐ The drawing(s) filed on is/are: a)☐ acce	epted or b) objected to by the E	xaminer.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some ★ c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
AMachan and (a)						
Attachment(s)  Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)						
2) Notice of Praftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	te				
B) Information Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal Pa	atent Application				
Paper No(s)/Mail Date	6) Other:					

Art Unit: 1614

## **DETAILED ACTION**

## Election/Restrictions

This application contains claims directed to the following patentably distinct species:

A method for ameliorating chemotherapeutic agent induced mucosal injury comprising administering to a patient an effective amount of a thiol-based composition prior to, concurrently with, or following the administration of chemotherapeutic agents where the thiol-based composition comprises:

- (a-1) N-acetylcysteine, no sodium thiosulfate
- (a-2) sodium thiosulfate, no N-acetylcysteine
- (a-3) both N-acetylcysteine and sodium thiosulfate
- (a-4) any compound from the list of claim 11 but that is not (a-1)–(a-3); the applicant is required to specify one compound or one mixture of specified compounds
  - (a-5) any compound or mixture that is not in the list of claim 11

In addition, further species election is required as follows for the chemotherapeutic agent in the method of treatment:

- (b-1) carboplatin
- (b-2) BR96-dox
- (b-3) cisplatin
- (b-4) oxyplatin

Art Unit: 1614

(b-5) any platinum-containing alkylating agent that is not (b-1)–(b-4); the applicant is required to specify one agent

- (b-6) any alkylating agent that is not (b-1)–(b-5)
- (b-7) any chemotherapeutic agent that is not (b-1)–(b-6)

The species are independent or distinct because they are different compounds. Different compounds have different structures, binding activities and biological effects. The interactions between every two different compounds are different. Searching for one compound is not likely to result in finding art pertinent to any other compounds.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-20 and 23-24 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

Art Unit: 1614

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nancy L. Zhang whose telephone number is (571)-272-8270. The examiner can normally be reached on Mon.- Fri. 8:30am - 5:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on (571)-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1614

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

neny 10/10/06

NLZ

Page 5

SUPERVISORY PATENT EXAMINER